Clinical Features:
X-linked Female-limited Epilepsy with Mental retardation (EFMR, OMIM#300088) is characterized by seizure onset in infancy or early childhood (6-36 months) and cognitive impairment. Seizures are predominantly generalized, including tonic-clonic, myoclonic, tonic, and atonic seizures. The spectrum of phenotypes has been extended to include female patients with early onset epileptic encephalopathies resembling Dravet syndrome or focal epilepsy with or without mental retardation (1).

Molecular Genetics
EFMR is caused by mutations in PCDH19 (protocadherin 19; OMIM#300460), located at Xq22. Protocadherins form a subfamily of calcium-dependent cell-cell adhesion molecules in the cadherin superfamily, and PCDH19 has been found to be expressed in the central nervous system, including the hippocampus and cortex, suggesting a role in cognitive function. Marini et al. (2010) identified 13 different mutations in the PCDH19 gene in 13 (11%) of 117 female patients with febrile seizures and a wide spectrum of epilepsy phenotypes (2). Gross and partial deletions of PCDH19 have also been reported (3).

Inheritance:
PCDH19 mutations are X-linked, with the phenotype being restricted to females. Males with hemizygous mutations are apparently unaffected with normal cognitive functions. This unusual mode of inheritance is likely to be due to cellular interference, a mechanism assuming that only the co-existence of PCDH19 positive and negative cells, as a result of random X inactivation in females, is pathogenic (3).

Test methods:
Comprehensive sequence coverage of the coding regions and splice junctions of the PCDH19 gene is performed. Targets of interests are enriched and prepared for sequencing using the Agilent SureSelect system. Sequencing is performed using Illumina technology and reads are aligned to the reference sequence. Variants are identified and evaluated using a custom collection of bioinformatic tools and comprehensively interpreted by our team of directors and genetic counselors. All pathogenic and likely pathogenic variants are confirmed by Sanger sequencing. The technical sensitivity of this test is estimated to be >99% for single nucleotide changes and insertions and deletions of less than 20 bp. Deletion/duplication analysis is performed by oligonucleotide array-CGH. Partial exonic copy number changes and rearrangements of less than 400 bp may not be detected by array-CGH. Array-CGH will not detect low-level mosaicism, balanced translocations, inversions, or point mutations that may be responsible for the clinical phenotype. The sensitivity of this assay may be reduced when DNA is extracted by an outside laboratory. PCDH19 sequence analysis is also offered as part of our Early Infantile Epileptic Encephalopathy Panel (see website for more details).

PCDH19 sequencing analysis
- Sample specifications: 3 to 10 cc of blood in a purple top (EDTA) tube
- Cost: $1000
- CPT codes: 81404
- Turn-around time: 4 weeks

PCDH19 deletion/duplication analysis
- Sample specifications: 3 to 10 cc of blood in a purple top (EDTA) tube
- Cost: $1000
- CPT codes: 81403
- Turn-around time: 4 weeks

Note: The sensitivity of our assay may be reduced when DNA is extracted by an outside laboratory.

Results:
Results, along with an interpretive report, are faxed to the referring physician as soon as they are completed. Additional reports are available as requested. All abnormal results are reported by telephone.
For more information about our testing options, please visit our website at dnatesting.uchicago.edu or contact us at 773-834-0555.

References: